Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
The purpose of this phase I/Ib open-label, non-controlled study is to investigate the safety, efficacy and pharmacokinetics (PK) of NBF-006 in patients with advanced non-small cell lung cancer (NSCLC), pancreatic, or colorectal cancer.
Study ID: NBF-006-001
Trial Phase: Phase I
Trial Sponsor: Nitto BioPharma, Inc.
Therapies Used in This Trial: NBF-006